Clinical effect and mechanism of estrogenic drugs in bone targeting therapy for osteoporosis Mechanism of estrogenic drugs in osteoporosis

Main Article Content

Yonggang Ma
Zhen Chai
Longlong Ren
Qiaolong Hu


Estrogen; Bazedoxifene; Osteoporosis; Clinical effect



To observe the clinical effect of estrogenic drugs (Bazedoxifene) on bone targeting in the treatment of osteoporosis and explore its mechanism.


112 patients with postmenopausal osteoporosis who received bardoxifene drugs in our hospital from January to December 2018 were collected as study group, and 56 patients treated with calcium alone were collected as control group. the risk of adverse events such as bone mineral density, osteoprotegerin (OPG), insulin-like growth factor (IGF), tumor necrosis factor (TNF-α), and fracture after treatment were analyzed before and after treatment. Results

There was no significant difference in the mean lumbar positive position (L2-4) and right femoral neck bone density and OPG、IGF、TNF-α level between the two groups before treatment (P>0.05). The total effective rate of clinical treatment in the study group was 88.39%, the control group was 23.21%, the difference between the two groups was statistically significant (P<0.05). After treatment, the mean lumbar positive position (L2-4) and the right femoral neck bone density and OPG、IGF in the study group were higher than those in the control group, lower than that in the control group (P<0.05). the occurrence of adverse events such as fracture, spinal deformation and fatigue in the study group after 12 months of treatment was significantly lower than that in the control group (P<0.05), but there was no significant difference in the occurrence of hot flashes and venous thromboembolism between the two groups (P>0.05).


Bazedoxifene is an effective drug for the treatment of postmenopausal osteoporosis. It can not only prevent the rapid loss of bone mass, effectively relieve the symptoms of menopause, but also improve bone density and reduce the risk of fracture.


Download data is not yet available.
Abstract 1 | PDF Downloads 0


[1] Coughlan T,Dockery F.Osteoporosis and fracture risk in older people[J]. Clinical medicine (London, England),2014,142:187-191.
[2] Xiang D,He J,Jiang T. The correlation between estrogen receptor gene polymorphism and osteoporosis in Han Chinese women[J]. European review for medical and pharmacological sciences,2018,22(23):8084-8090.
[3] Figliomeni A,Signorini V,Mazzantini M.One year in review 2018: progress in osteoporosis treatment[J].Clinical and experimental rheumatology,2018,366:948-958.
[4] Chen L R,Ko N Y,Chen K H. Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions[J]. International journal of molecular sciences,2019,20(9):E2213.
[5] Schnitzer T J. Estrogen therapy in postmenopausal women[J]. Current rheumatology reports,2003,51:43-44.
[6] Xing Q,Tang P,Gao Y,et al. Proteomic analysis of estrogen mediated Signal Transduction in Osteoclasts Formation[J].Biomed Res Int,2015,2015: 596789.
[7] Hofbauer L C,Khosla S,Dunstan C R,et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells[J]. Endocrinology,1999,1409:4367-4370.
[8] Mano H,Hakeda Y,Kumegawa M.Estrogen directly down-regulates the bone-resorbing activity of mature osteoclasts through nuclear estrogen receptor alpha[J]. Cytotechnology,2001,351:17-23.
[9] Orimo H,Hayashi Y,Fukunaga M,et al. Diagnostic criteria for primary osteoporosis: year 2000 revision[J]. Journal of bone and mineral metabolism,2001,196:331-337.
[10] Li Z,Yuan G,Lin X,et al. Dehydrocostus lactone (DHC) suppresses estrogen deficiency-induced osteoporosis[J].Biochemical pharmacology,2019,163:279-289.
[11] Duursma S A,Raymakers J A,Boereboom F T,et al. Estrogen and bone metabolism[J].Obstetrical & gynecological survey,1992,471:38-44.
[12] Mesalić L,Tupković E,Kendić S,et al.Correlation between hormonal and lipid status in women in menopause[J].Bosnian Journal of Basic Medical Sciences,2008,8(2):188-92.
[13] Levin V A,Jiang X,Kagan R.Estrogen therapy for osteoporosis in the modern era[J].Osteoporosis international,2018,295:1049-1055.
[14] Hofbauer L C,Heufelder A E. Osteoprotegerin:a novel local player in bone metabolism[J].European journal of endocrinology,1997,1374:345-346.
[15] Yasuda H,Shima N,Nakagaw a N,et al.Ost eoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibit ory f actor and is iden tical to T RANCE/RANKL[J].Proc Natl Acad Sci USA,1998,95:3597-3602.
[16] Lacey D L,Timms E,Tan H L,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[J]. Cell,1998,932:165-176.
[17] Ferretti C,Vozzi G,Falconi M,et al. Role of IGF1 and IGF1/VEGF on human mesenchymal stromal cells in bone healing: two sources and two fates[J]. Tissue engineering.Part A,2014,2017(18):2473-2482.
[18] Jehle P M,Schulten K,Schulz W,et al. Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients[J]. European journal of internal medicine,2003,141:32-38.
[19] Sang C,Zhang Y,Chen F,et al.Tumor necrosis factor alpha suppresses osteogenic differentiation of MSCs by inhibiting semaphorin 3B via Wnt/β-catenin signaling in estrogen-deficiency induced osteoporosis[J].Bone,2016,84:78-87.
[20] Sun M,Yang J,Wang J,et al. TNF-α is upregulated in T2DM patients with fracture and promotes the apoptosis of osteoblast cells in vitro in the presence of high glucose[J].Cytokine,2016,80:35-42.